ibuzatrelvir

Phase 3Small molecule

Pfizer

ibuzatrelvir is one of 18 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19 InfectionRecruiting

SARS Cov 2 InfectionRecruiting

COVID-19Phase 3

Active, not recruiting

COVID-19 InfectionPhase 3

Recruiting

SARS Cov 2 InfectionPhase 3

Recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

ibuzatrelvir

Pfizer

Phase 3

4 2

Singulair

AstraZeneca

Preclinical

1 3

Aldactone

Pfizer

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 7

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

COVID-19 Infection

NCT07013474

Phase 3Recruiting

SARS Cov 2 Infection

NCT06679140

Clinical

Trials by Indication[1]

Adult2 trials

A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT07235137·12 enrolled

A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT06646042·12 enrolled

COVID-19 Infection1 trial

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELY IMMUNOCOMPROMISED

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07013474·300 enrolled

SARS CoV 2 Infection1 trial

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT06679140·2,330 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ibuzatrelvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ibuzatrelvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ibuzatrelvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

ibuzatrelvir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Adult2 trials

COVID-19 Infection1 trial

SARS CoV 2 Infection1 trial

References

Drug Info

Quick Facts

Related News